Sign in

You're signed outSign in or to get full access.

Howard Doss

Director at Aspire Biopharma Holdings
Board

About Howard Doss

Howard Doss, age 71, is an independent Class I director of Aspire Biopharma Holdings, Inc. (ASBP) and serves as Chair of the Audit Committee; he was appointed to the Board on July 24, 2025 and qualifies as an SEC-defined “audit committee financial expert.” He is a seasoned CFO and accountant with prior CFO roles at multiple public companies/SPACs and is a member of the American Institute of CPAs; he is a graduate of Illinois Wesleyan University. He beneficially owns 400,000 ASBP shares (<1% of outstanding) as of September 2025.

Past Roles

OrganizationRoleTenureCommittees/Impact
PowerUpChief Financial OfficerAug 2023 – Feb 2025Senior finance oversight; public company CFO experience
Kernel Group Holdings, Inc. (SPAC)Chief Financial Officer2021SPAC finance leadership
Aesther Healthcare Acquisition Corp. (SPAC)Chief Financial Officer2021 – Feb 2023Led finance through business combination
Trade Health, Inc. (Nasdaq: SCNX)Chief Financial OfficerNot disclosedCFO of Nasdaq-listed health marketplace
Sansur Renewable EnergyCFO and Director2010 – 2012Alternative energy; board role
STARadio Corp.PresidentSince 2005Operating leadership
U.S. Trust (Sarasota)City ExecutiveUntil 2009Managed HNW client operations
Principal Financial Group (Tampa)Finance roleNot disclosedInstitutional finance experience
Franklin TempletonFinance roleNot disclosedAsset management experience
Van Kampen InvestmentsOpened Southeast office (Tampa)1982 – 1996Institutional distribution/leadership
Seidman & Seidman (BDO Seidman, Dallas)Staff accountant1977 – 1980Accounting foundation

External Roles

OrganizationRoleTenureNotes
American Institute of CPAsMemberOngoingProfessional credential
Illinois Wesleyan UniversityGraduateOngoingEducation

Board Governance

  • Independence: Board determined Doss is independent under Nasdaq and SEC rules.
  • Committee assignments: Audit Committee (Chair); Compensation Committee (Member).
  • Audit financial expert: Board determined Doss qualifies as an “audit committee financial expert.”
  • Appointment timing: Appointed Director and Audit Chair on July 24, 2025 during leadership transition.
  • Board structure: Five directors; classified board (Doss is Class I, term expires at first annual meeting post-Closing).
  • Independent director sessions: Independent directors to hold regularly scheduled meetings (executive sessions).

Fixed Compensation

ComponentAmountNotes
Fees Earned or Paid in Cash ($)$0“None of our Non-Employee Directors has received any cash compensation for services rendered to us.”

Performance Compensation

  • No director option/equity awards recorded to date in the Director Compensation disclosure table (no amounts shown for option awards).
  • No performance metrics for director compensation disclosed (e.g., TSR, revenue, EBITDA) in available filings.

Other Directorships & Interlocks

  • Current public company boards: None disclosed beyond ASBP.
  • Prior board role: Director at Sansur Renewable Energy (2010–2012).
  • Interlocks: No disclosed shared public-company directorships with ASBP competitors/suppliers/customers; no related-party transactional interlocks identified.

Expertise & Qualifications

  • Deep CFO experience across public companies/SPACs and operating roles; strong financial reporting and controls background.
  • Audit committee financial expert; financially literate per board designation.
  • AICPA membership; finance and accounting career across BDO, Van Kampen, Franklin Templeton, Principal, U.S. Trust.
  • Education: Illinois Wesleyan University.

Equity Ownership

HolderShares Beneficially Owned% of OutstandingReference Base (Shares Outstanding)
Howard Doss400,000<1%49,525,970 Common shares outstanding as of Sep 10/25

Governance Assessment

  • Strengths: Independent audit chair with “financial expert” designation; committee charters emphasize pre-approval and oversight of related-party transactions, conflicts, and disclosure controls—key for investor confidence in a small-cap with financing complexity.
  • Alignment: Beneficial ownership present (400,000 shares), albeit <1% of outstanding; no cash director fees to date, limiting fixed pay “rent.”
  • Transition oversight: Appointment as Audit Chair amid CEO and board changes provides continuity on controls and disclosure during volatility.
  • Areas to monitor (potential RED FLAGS at company level impacting board effectiveness):
    • Financing/dilution risk: Convertible notes with potential issuance of 73,588,712 shares at a floor price, creating substantial dilution and pressure on governance of capital allocation.
    • Listing compliance: Board is pursuing a reverse stock split to maintain Nasdaq minimum bid price compliance—execution and investor communication will test board effectiveness.
  • Conflicts/related-party exposure: No Doss-specific related-party transactions disclosed; audit committee charter requires pre-approval and oversight of related-party dealings.

Overall: Doss brings robust finance and audit oversight to ASBP’s board during a period of capital-structure stress and listing-compliance actions. As audit chair and financial expert, his leadership on disclosure controls, related-party review, and financing transparency is a key governance anchor; monitoring dilution mechanics, control environment, and independent director engagement will be critical for investor confidence.